Prediction Case File
YouTubeTracking Live

Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community

1 extracted signal · 0 resolved · 1 still active

Parkev Tatevosian, CFA profile imageParkev Tatevosian, CFAIndependent analyst profile
Source published
21 Nov 2025, 01:41 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
Source overview

AI-generated source summary

On November 3rd, 2025, an analysis was conducted on Palantir Technologies (PLTR), advising investors against purchasing the stock. This recommendation was made despite the company demonstrating excellent business performance metrics, including accelerating revenue growth, expanding profit margins, increasing cash flow from operations to sales, and a premium return on invested capital. The core reasoning for the 'do not buy' stance was the stock's valuation, which was deemed too expensive when assessed using both a forward price-to-earnings ratio and a proprietary discounted cash flow (DCF) model. The DCF model specifically yielded an intrinsic share value of $79.02, significantly below the current market price of $165.49. Subsequent to this analysis, free cash flow expectations for Palantir were upgraded, and its risk profile was reportedly downgraded by adjusting its Beta coefficient to 0.8. This adjustment indicated a perception that the company was 80% as risky as in prior periods. Despite these positive internal adjustments and strong operational performance, the fundamental valuation consistently indicated overvaluation, leading to the reiterated 'do not buy' recommendation.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

Parkev Tatevosian, CFA

Platform-wide history, separate from this source evaluation.

Reliability
41.8
Tracked signals
1293
Historical success
25.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail